Pharmaceuticals Novartis continues to grow in Q3, but pace slows down
Novartis continued its growth trend in the third quarter, albeit at a slower pace as a result of increasing generic competition. The Basel-based company has confirmed its outlook for the year as a whole, having previously raised it for ten consecutive quarters.
28.10.2025, 07:32
SDA
As Novartis announced on Tuesday, sales in the third quarter climbed to 13.9 billion US dollars. This is an increase of 8 percent compared to the same period last year. At constant exchange rates (CER), growth amounted to 7 percent. This means that the pace of growth has clearly slowed compared to the previous quarter (+12%).
The Basel-based company recorded a 24% increase in operating profit to 4.5 billion. The bottom line was a consolidated profit of 3.9 billion after 3.2 billion in the same period of the previous year. The increase was mainly due to the higher operating result, the press release continued.
For analysts, however, the core operating profit adjusted for various factors is the most important factor. At just under 5.5 billion, this increased by 6 percent and was therefore just below the AWP consensus of just under 5.6 billion.
Outlook confirmed
For the full year, Novartis management is confirming its previous guidance, which had previously been raised for ten consecutive quarters. At constant exchange rates, the Group continues to aim for sales growth in the high single-digit percentage range. For core operating profit, it is forecasting an increase in the low teens.
